Uterine Corpus Leiomyosarcoma — Trials

Uterine Corpus Leiomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

22 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: City of Hope Medical Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01012297	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma	terminated	Phase 3	107	National Cancer Institute (NCI)NIH	1	Jun 24, 2026	clinicaltrials
NCT01958580	Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery	terminated	N/A	3	Albert Einstein College of MedicineOTHER	1	Aug 16, 2023